<DOC>
	<DOCNO>NCT02330419</DOCNO>
	<brief_summary>This double-blind , placebo-controlled trial 120 binge-drinking MSM 12 week naltrexone 50mg , take anticipation heavy drinking . Ethnically racially diverse participant recruit use Respondent Driven Sampling well active field recruitment . MSM see weekly alcohol-metabolite urine testing , study drug dispensing , brief counsel alcohol use . Safety assessment behavioral survey complete monthly .</brief_summary>
	<brief_title>Say When : Targeting Heavy Alcohol Use With Naltrexone Among MSM</brief_title>
	<detailed_description />
	<mesh_term>Binge Drinking</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>( 1 ) Male gender ( 2 ) selfreported anal sex men prior three month influence alcohol ( 3 ) least one binge drinking ( five drink single occasion ) session per week prior three month ; ( 4 ) interested reduce binge alcohol consumption ; ( 5 ) HIVnegative rapid antibody test medical record documentation HIV infection ( HIV positive participant ) ; ( 6 ) current acute illness require prolong medical care ; ( 7 ) chronic illness likely progress clinically trial participation ; ( 8 ) able willing provide inform consent adhere visit schedule ; ( 9 ) age 1870 year ; ( 10 ) baseline CBC , total protein , albumin , glucose , alkaline phosphatase , creatinine , BUN , electrolytes without clinically significant abnormality determine study clinician conjunction symptom , physical exam , medical history . ( 1 ) Any psychiatric ( e.g . depression suicidal ideation ) medical condition would preclude safe participation study ; ( 2 ) know allergy/previous adverse reaction naltrexone ; ( 3 ) current use of/ dependence opioids know medical condition currently requires/may likely require opioid analgesic ; ( 4 ) opioidpositive urine enrollment ; ( 5 ) current CD4 count &lt; 200 cells/mm3 ( 6 ) moderate/severe liver disease ( AST , ALT &gt; 3 time upper limit normal ) ; ( 7 ) impair renal function ( creatinine clearance &lt; 50 ml/min ) ; ( 8 ) currently participate another intervention research study potential overlap ; ( 9 ) alcohol dependence determine SCID criterion ( participant nondependent alcohol use disorders/symptoms alcohol abuse [ per DSMIV ] eligible ) ( 10 ) condition , principal investigator and/or study clinician 's judgment interfere safe study participation adherence study procedure ; ( 11 ) cellphone send receive text message .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Naltrexone</keyword>
</DOC>